Getting Underway At Pathology Visions 2023

This October, as the vibrant city of Orlando plays host to Pathology Visions 2023 at the prestigious Hyatt Regency, we at Pathology News are filled with anticipation and excitement. From October 29th to 31st, this event, proudly presented by the Digital Pathology Association, promises to be a cornerstone for the latest in digital pathology, bringing together the brightest minds and innovators in the field.

This year’s conference offers an exceptional blend of workshops, keynote addresses, and insightful presentations, promising to advance our understanding of digital pathology and its intersection with artificial intelligence. The agenda is packed with groundbreaking topics, ranging from AI-driven solutions for tissue staining standardization to the challenges and opportunities presented by large language models in diagnostic pathology.

We are particularly excited about the diverse array of exhibitors and sponsors, each bringing unique insights and innovations to the table. These industry leaders are not just showcasing their latest offerings but are actively engaging in the dialogue about the future of pathology. As attendees you will have the opportunity to interact with these pioneers, gaining insights into the latest technologies and strategies that are shaping the future of healthcare.

We encourage everyone attending to make the most of this event by visiting the exhibitor stands and participating actively in the workshops and sessions. Each sponsor and exhibitor at Pathology Visions 2023 has something unique to contribute to our collective understanding and advancement in the field. See below for more information on this year’s key exhibitors.

Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture.  Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is headquartered in Germany and operates in over 100 countries.
BOOTH: 205

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more.

BOOTH: 213

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

BOOTH: 313

Philips is a health technology company focused on improving people’s lives through meaningful innovation across the health continuum – from healthy living and prevention to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips partners with customers to deliver integrated solutions that address the Quadruple Aim: improved patient experience, better health outcomes, improved staff experience, and lower cost of care.

BOOTH: 113

The Roche VENTANA product portfolio represents a legacy of innovation and includes automated instruments and reagent systems for slide-based tissue diagnostics for cancer and infectious disease. In addition to fully automated slide staining platforms and specimen workflow software, Roche offers a digital pathology portfolio that includes scanners for whole slide imaging, software to manage the digital workflow, and companion image analysis algorithms. These digital solutions are designed to help AP labs improve workflow efficiency, ensure patient and user safety, and empower precision medicine.

BOOTH: 200

Tribun Health is a leading provider of AI-powered digital pathology solutions, transforming the way pathologists diagnose and treat diseases. Our advanced technology, combined with our clinical and informatics expertise, delivers unparalleled accuracy, speed, and efficiency in pathology diagnosis. We have been recognized as a two-time Best in KLAS award winner (2022 & 2023) for our excellence in customer satisfaction and continue to be recognized for our innovative approach to digital pathology and commitment to customer success. Tribun Health is a pioneer in digital pathology workflow solutions with image acquisition, image storage, web-based image management system, image analysis using AI-powered deep and machine learning algorithms, remote case sharing with peer review (telepathology) and reporting. Visit our website at www.tribun.health to learn more about our end-to-end digital pathology platform.

BOOTH: 307

Indica Labs is the world’s leading provider of computational pathology software and image analysis services. Our flagship HALO® and HALO AI platform facilitates quantitative evaluation of digital pathology images. HALO Link facilitates research-focused image management and collaboration while HALO AP® enables collaborative clinical case review. Through a combination of precision, performance, scalability, and usability our software solutions enable pharmaceutical companies, diagnostic labs, research organizations, and Indica’s own contract pharma services team to advance tissue-based research, clinical trials, and diagnostics.

BOOTH: 216

Deep Bio refers to a biomedical solution using deep learning technology and is a biotech startup that develops AI software for cancer diagnosis based on medical data. Deep Bio aims to simplify existing work procedures for pathologists by combining state-of-the-art AI algorithms with digital pathology and helping them make more accurate judgments and diagnoses. DeepDx™, a cancer diagnosis model developed by Deep Bio based on an excellent talent pool with world-class medical and deep learning technology, uses Convolutional Neural Network (CNN) among deep learning methods to determine the presence and severity of cancer lesions in pathological tissue images. and provides functions that help pathologists extract diagnosis reports.

BOOTH: 403

Lumea’s DaVincian team developed and commercialized the most advanced digital pathology platform on the market today. Their solutions standardized and connected clinic, laboratory, and pathology workflows. This digital pathology company has deployed proprietary tissue handling technologies, specimen tracking, laboratory efficiency improvements, a seamless digital signout process, and added invaluable AI and genetic testing partnerships to improve the quality of practices and allows businesses to scale.

BOOTH: 219

Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.

BOOTH: 203

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq® digital pathology platform and powerful AI applications are advancing the 150-year old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and over 10 of the top 20 pharmaceutical companies rely on Proscia’s software each day.

BOOTH: 101

Share This Post

Leave a Reply